These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 23404293)

  • 1. Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells.
    Vaňhara P; Horak P; Pils D; Anees M; Petz M; Gregor W; Zeillinger R; Krainer M
    Int J Oncol; 2013 Apr; 42(4):1383-9. PubMed ID: 23404293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo.
    Horak P; Tomasich E; Vaňhara P; Kratochvílová K; Anees M; Marhold M; Lemberger CE; Gerschpacher M; Horvat R; Sibilia M; Pils D; Krainer M
    Sci Rep; 2014 Jan; 4():3739. PubMed ID: 24435307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells.
    Kratochvílová K; Horak P; Ešner M; Souček K; Pils D; Anees M; Tomasich E; Dráfi F; Jurtíková V; Hampl A; Krainer M; Vaňhara P
    Int J Cancer; 2015 Sep; 137(6):1330-40. PubMed ID: 25735931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TUSC3: functional duality of a cancer gene.
    Vašíčková K; Horak P; Vaňhara P
    Cell Mol Life Sci; 2018 Mar; 75(5):849-857. PubMed ID: 28929175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation status of TUSC3 is a prognostic factor in ovarian cancer.
    Pils D; Horak P; Vanhara P; Anees M; Petz M; Alfanz A; Gugerell A; Wittinger M; Gleiss A; Auner V; Tong D; Zeillinger R; Braicu EI; Sehouli J; Krainer M
    Cancer; 2013 Mar; 119(5):946-54. PubMed ID: 23096450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TUSC3 accelerates cancer growth and induces epithelial-mesenchymal transition by upregulating claudin-1 in non-small-cell lung cancer cells.
    Feng S; Zhai J; Lu D; Lin J; Dong X; Liu X; Wu H; Roden AC; Brandi G; Tavolari S; Bille A; Cai K
    Exp Cell Res; 2018 Dec; 373(1-2):44-56. PubMed ID: 30098333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased TUSC3 Promotes Pancreatic Cancer Proliferation, Invasion and Metastasis.
    Fan X; Zhang X; Shen J; Zhao H; Yu X; Chen Y; Zhuang Z; Deng X; Feng H; Wang Y; Peng L
    PLoS One; 2016; 11(2):e0149028. PubMed ID: 26871953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of substrate specificity of human oligosaccharyl transferase subunit N33/Tusc3 and its role in regulating protein N-glycosylation.
    Mohorko E; Owen RL; Malojčić G; Brozzo MS; Aebi M; Glockshuber R
    Structure; 2014 Apr; 22(4):590-601. PubMed ID: 24685145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour suppressor candidate 3 inhibits biological function and increases endoplasmic reticulum stress of melanoma cells WM451 by regulating AKT/GSK3-β/β-catenin pathway.
    Wang S; Zhu W
    Cell Biochem Funct; 2020 Jul; 38(5):604-612. PubMed ID: 32090352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TUSC3: a novel tumour suppressor gene and its functional implications.
    Yu X; Zhai C; Fan Y; Zhang J; Liang N; Liu F; Cao L; Wang J; Du J
    J Cell Mol Med; 2017 Sep; 21(9):1711-1718. PubMed ID: 28272772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TUSC3 induces drug resistance and cellular stemness via Hedgehog signaling pathway in colorectal cancer.
    Ren Y; Deng R; Cai R; Lu X; Luo Y; Wang Z; Zhu Y; Yin M; Ding Y; Lin J
    Carcinogenesis; 2020 Dec; 41(12):1755-1766. PubMed ID: 32338281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A defect in the TUSC3 gene is associated with autosomal recessive mental retardation.
    Garshasbi M; Hadavi V; Habibi H; Kahrizi K; Kariminejad R; Behjati F; Tzschach A; Najmabadi H; Ropers HH; Kuss AW
    Am J Hum Genet; 2008 May; 82(5):1158-64. PubMed ID: 18452889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OST4 is a subunit of the mammalian oligosaccharyltransferase required for efficient N-glycosylation.
    Dumax-Vorzet A; Roboti P; High S
    J Cell Sci; 2013 Jun; 126(Pt 12):2595-606. PubMed ID: 23606741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TUSC3 suppresses glioblastoma development by inhibiting Akt signaling.
    Jiang Z; Guo M; Zhang X; Yao L; Shen J; Ma G; Liu L; Zhao L; Xie C; Liang H; Wang H; Zhu M; Hu L; Song Y; Shen H; Lin Z
    Tumour Biol; 2016 Sep; 37(9):12039-12047. PubMed ID: 27177902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selenoprotein T is a novel OST subunit that regulates UPR signaling and hormone secretion.
    Hamieh A; Cartier D; Abid H; Calas A; Burel C; Bucharles C; Jehan C; Grumolato L; Landry M; Lerouge P; Anouar Y; Lihrmann I
    EMBO Rep; 2017 Nov; 18(11):1935-1946. PubMed ID: 28928140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic function of TUSC3 in non-small cell lung cancer is associated with Hedgehog signalling pathway.
    Gu Y; Pei X; Ren Y; Cai K; Guo K; Chen J; Qin W; Lin M; Wang Q; Tang N; Cheng Z; Ding Y; Lin J
    Biochim Biophys Acta Mol Basis Dis; 2017 Jul; 1863(7):1749-1760. PubMed ID: 28487226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oligosaccharyltransferase-subunit mutations in nonsyndromic mental retardation.
    Molinari F; Foulquier F; Tarpey PS; Morelle W; Boissel S; Teague J; Edkins S; Futreal PA; Stratton MR; Turner G; Matthijs G; Gecz J; Munnich A; Colleaux L
    Am J Hum Genet; 2008 May; 82(5):1150-7. PubMed ID: 18455129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian cells lacking either the cotranslational or posttranslocational oligosaccharyltransferase complex display substrate-dependent defects in asparagine linked glycosylation.
    Cherepanova NA; Gilmore R
    Sci Rep; 2016 Feb; 6():20946. PubMed ID: 26864433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TUSC3 promotes colorectal cancer progression and epithelial-mesenchymal transition (EMT) through WNT/β-catenin and MAPK signalling.
    Gu Y; Wang Q; Guo K; Qin W; Liao W; Wang S; Ding Y; Lin J
    J Pathol; 2016 May; 239(1):60-71. PubMed ID: 27071482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer.
    Burgermeister E; Höde P; Betge J; Gutting T; Merkel A; Wu W; Tänzer M; Mossner M; Nowak D; Magdeburg J; Rückert F; Sticht C; Breitkopf-Heinlein K; Schulte N; Härtel N; Belle S; Post S; Gaiser T; Heppner BI; Behrens HM; Röcken C; Ebert MPA
    Oncotarget; 2017 Oct; 8(49):84714-84728. PubMed ID: 29156678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.